Background

Osteosarcoma is a type of bone cancer that primarily affects the long bones, such as those in the arms and legs. It is an aggressive and rare form of cancer that most commonly occurs in adolescents and young adults, but it can also affect older individuals.

Osteosarcoma often develops in the metaphyseal region of the bone, which is the area where the bone is growing. Osteosarcoma arises from osteoblasts, which are the cells responsible for forming new bone tissue. The production of immature bone or osteoid tissue characterizes it. 

Epidemiology

Osteosarcoma is a relatively rare form of cancer, accounting for approximately 2.4% of all childhood cancers. 

Incidence: 

• It is most commonly diagnosed in adolescents and young adults. 
• The incidence is higher in individuals aged 10 to 24 years, with a peak during the adolescent growth spurt. 
• It is a rare cancer in adults, comprising only a small percentage of bone cancers in older age groups. 

Age Distribution: 

• Osteosarcoma primarily affects individuals in their second decade of life, with the median age of diagnosis being around 15 years. 
• It is less common in younger children and older adults, though it can occur at any age. 

Gender Predilection: 

• Osteosarcoma has a slight preference for males, with a male-to-female ratio of approximately 1.4:1. 
• This gender difference is more pronounced in the adolescent and young adult age groups. 

Race and Ethnicity: 

• There is some evidence suggesting variations in osteosarcoma incidence among different racial and ethnic groups. 
• In the United States, for example, osteosarcoma appears to be more common in individuals of African and Hispanic descent compared to Caucasians. 

Geographic Variation: 

• Osteosarcoma incidence rates may vary geographically, with some studies suggesting higher rates in certain regions. 
• The reasons for geographic variation are not entirely understood and may be influenced by genetic, environmental, or other factors. 

Anatomy

Pathophysiology

• Genetic Predisposition: Osteosarcoma can occur sporadically, but some cases are associated with genetic predisposition. Certain hereditary conditions, such as hereditary retinoblastoma and Li-Fraumeni syndrome, increase the risk of developing osteosarcoma. 
• Genetic Alterations: Specific genetic mutations play a role in the initiation and progression of osteosarcoma. Mutations in tumor suppressor genes (e.g., TP53 and RB1) and other genes involved in cell cycle regulation are commonly observed. 
• Cellular Transformation: Osteosarcoma originates from mesenchymal stem cells or osteoblasts, which undergo genetic alterations that transform them into cancerous cells. This transformation leads to uncontrolled cell proliferation. 
• Osteoid Production: One hallmark of osteosarcoma is the production of osteoid, an immature bone matrix. Malignant cells within the tumor actively produce osteoid tissue, contributing to the formation of abnormal bone. 
• Tumor Formation: Osteosarcomas often develop in the metaphyseal region of long bones, where rapid bone growth occurs during adolescence. The presence of malignant osteoblasts, osteoid tissue, and mineralized bone characterizes tumors. 
• Local Invasion: Osteosarcomas can invade and destroy adjacent normal bone tissue. This local invasiveness can lead to bone destruction and structural deformities. 
• Metastasis: Osteosarcoma has a strong tendency to metastasize, commonly to the lungs. The metastatic spread is primarily hematogenous, and the presence of metastases significantly influences the prognosis. 
• Angiogenesis: Tumor growth requires the development of a blood supply. Osteosarcomas induces angiogenesis, the formation of new blood vessels, to provide nutrients and oxygen to support the growing tumor. 

Etiology

Genetic Factors: 

• Hereditary Syndromes: Some individuals with hereditary cancer predisposition syndromes, such as Li-Fraumeni syndrome and hereditary retinoblastoma, have an increased risk of developing osteosarcoma. 
• Genetic Mutations: Specific genetic mutations are associated with osteosarcoma, particularly mutations in tumor suppressor genes like TP53 and RB1. These mutations can lead to uncontrolled cell growth and the formation of tumors. 

Age and Growth Spurts: 

• Osteosarcoma most commonly occurs during periods of rapid bone growth, such as adolescence. The peak incidence is typically between the ages of 10 and 24 years. 
• The metaphyseal region of long bones, where osteosarcomas often develop, is an area of active bone growth during puberty. 

Radiation Exposure: 

• Exposure to ionizing radiation, especially at high doses, is a known risk factor for the development of osteosarcoma. This can be related to previous radiation therapy for other cancers or diagnostic procedures. 

Bone Disorders and Trauma: 

• Underlying bone disorders, such as Paget’s disease, may increase the risk of osteosarcoma. However, the majority of cases occur in individuals without a known predisposing condition. 
• Previous trauma or bone fractures are not direct causes of osteosarcoma but may be associated with the development of secondary sarcomas in some cases. 

Environmental Factors: 

• While specific environmental factors contributing to osteosarcoma are not well-defined, some studies have explored potential associations with exposure to certain chemicals or toxins. However, evidence linking environmental factors to osteosarcoma remains inconclusive. 

Genetics

Prognostic Factors

• Tumor Stage: The extent of the disease, often described using the TNM staging system (Tumor, Node, Metastasis), is a crucial prognostic factor. Higher stages indicate more advanced disease and are associated with a poorer prognosis. 
• Histological Response to Neoadjuvant Chemotherapy: The response of the tumor to pre-surgical (neoadjuvant) chemotherapy is an important prognostic factor. A good histological response, meaning significant tumor necrosis, is associated with a better prognosis. 
• Tumor Size and Location: Larger tumors or those located in anatomically challenging areas may be associated with a poorer prognosis. Tumors located in the axial skeleton, such as the spine or pelvis, may be more challenging to treat. 
• Surgical Margins: The completeness of surgical resection is a critical factor in determining prognosis. Negative surgical margins (complete removal of the tumor without microscopic evidence of residual disease) are associated with a better outcome. 
• Metastasis at Diagnosis: The presence of metastases at the time of diagnosis significantly impacts prognosis. Osteosarcoma commonly metastasizes to the lungs, and the number and size of lung metastases are important considerations. 
• Age at Diagnosis: Younger age at diagnosis is generally associated with a better prognosis. Adolescents and young adults tend to have more favorable outcomes compared to older individuals. 
• Response to Chemotherapy: The overall response of the tumor to chemotherapy is a prognostic factor. Osteosarcoma is typically treated with multi-agent chemotherapy, and a good response is associated with improved outcomes. 
• Genetic and Molecular Factors: Specific genetic and molecular characteristics of the tumor may influence prognosis. For example, specific genetic mutations or alterations may be associated with a more aggressive course of the disease. 

Clinical History

Age Group: 

Adolescents and Young Adults (10-24 years): 

• Osteosarcoma most commonly presents during the adolescent growth spurt, with a peak incidence between the ages of 10 and 24. 
• Common sites of occurrence include the metaphyseal region of long bones, such as the distal femur, proximal tibia, and proximal humerus. 
• Symptoms may include localized pain, swelling, and tenderness near the affected bone. 
• Adolescents and young adults are more likely to have primary osteosarcoma without a known predisposing condition. 

Children (Younger than ten years): 

• Osteosarcoma is less common in children under 10 years old. 
• The presentation in younger children may be less specific, and symptoms might be attributed to other musculoskeletal issues. 
• Diagnosis in this age group may require careful evaluation and consideration of alternative diagnoses. 

Adults (25 years and older): 

• Osteosarcoma is relatively rare in adults but can occur. 
• When it occurs in adults, it often involves different sites, and the presentation may be similar to that in adolescents. 
• Adults with osteosarcoma may be more likely to have underlying predisposing conditions or prior exposure to radiation. 

Physical Examination

Inspection: 

• Swelling: Look for any visible swelling or deformity around the affected bone. Osteosarcomas often cause a palpable mass or swelling. 

• Skin Changes: Observe for any changes in the overlying skin, such as redness, warmth, or discoloration. Skin involvement may occur in advanced cases. 

Palpation: 

• Tenderness: Gently palpate the area around the affected bone for tenderness. Osteosarcoma is often associated with localized pain. 
• Temperature: Assess the temperature of the skin over the affected area. Increased warmth may indicate inflammation. 
• Palpable Mass: Identify any palpable masses or bony prominences that could indicate the presence of a tumor. 

Range of Motion: 

• Evaluate the range of motion of nearby joints, especially if the tumor is close to a joint. Osteosarcomas can affect joint function and cause limitations in movement. 

Functional Assessment: 

• Assess the patient’s ability to perform daily activities and note any functional impairment. Osteosarcomas in weight-bearing bones can affect mobility. 

Neurovascular Examination: 

• Assess neurovascular status, especially if the tumor is near nerves or blood vessels. Check for signs of nerve compression or vascular compromise. 

Lymph Node Examination: 

• Palpate regional lymph nodes to assess for any signs of lymphadenopathy. Lymph node involvement is not common in osteosarcoma, but it can occur in rare cases. 

Systemic Signs: 

• Fever: Inquire about and assess for signs of fever, as systemic symptoms may be present in advanced cases. 
• Weight Loss: Ask about unintentional weight loss, which can be a nonspecific sign of advanced disease. 

Assessment of Growth Plates (Pediatric Patients): 

• In pediatric patients, assess the growth plates in the area of concern. Osteosarcoma often occurs near the metaphyseal growth plates of long bones. 

Comparison with the Contralateral Side: 

• Compare the affected limb with the contralateral side to identify any asymmetry, deformity, or differences in size and shape. 

Skin Examination: 

• Check for any cutaneous lesions, ulceration, or signs of infection overlying the tumor site. 

Age group

Associated comorbidity

Hereditary Syndromes: 

• Individuals with hereditary cancer predisposition syndromes, such as Li-Fraumeni syndrome or hereditary retinoblastoma, may have an increased risk of developing osteosarcoma. 
• Surveillance and consideration of osteosarcoma risk may be part of the management for individuals with these syndromes. 

Paget’s Disease of Bone: 

• Osteosarcoma can develop in individuals with Paget’s disease of bone, a condition characterized by abnormal bone remodeling. 
• Paget’s disease may present with bone pain and deformities, and the risk of osteosarcoma development is increased in affected bones. 

Previous Radiation Exposure: 

• Individuals who have undergone previous radiation therapy, especially at a young age, may be at an increased risk of developing osteosarcoma in the irradiated area. 
• Radiation-related osteosarcomas may have a different clinical course compared to sporadic cases. 

Bone Trauma or Fractures: 

• While trauma or fractures are not direct causes of osteosarcoma, some cases have been reported in areas of previous bone trauma or surgical intervention. 

Associated activity

Acuity of presentation

Insidious Onset: 

• Osteosarcoma often presents with insidious onset, with symptoms gradually developing over time. 
• Patients may initially experience intermittent pain or swelling that progresses. 

Localized Pain and Swelling: 

• Localized pain at the site of the tumor is a common early symptom. 
• Swelling and tenderness over the affected bone are also typical, and the area may feel warm. 

Functional Impairment: 

• Depending on the location and size of the tumor, functional impairment and limitation of joint movement may occur. 

Systemic Symptoms: 

• Systemic symptoms, such as fever or weight loss, are generally uncommon but may be present in advanced cases or cases with metastasis. 

Symptoms Aggravated by Activity: 

• Pain and symptoms may be aggravated by physical activity or weight-bearing on the affected limb. 

Differential Diagnoses

• Ewing Sarcoma: It is another type of primary bone cancer that primarily affects children and young adults. It often occurs in the diaphysis (shaft) of long bones and can cause pain, swelling, and fever. 
• Chondrosarcoma: It is a malignant tumor that arises from cartilage cells. It can occur in the bones and may present with pain and swelling. Distinguishing it from osteosarcoma is essential for planning appropriate treatment. 
• Giant Cell Tumor of Bone: It is a locally aggressive, typically benign tumor that can occur around the knee joint. It may present with pain and swelling and can sometimes be confused with osteosarcoma. 
• Osteochondroma: It is a common benign bone tumor that usually appears during childhood or adolescence. It presents as a bony projection near the growth plate and is generally asymptomatic. 
• Enchondroma: Enchondromas are benign tumors that originate from cartilage within the bone. They are usually found incidentally in imaging studies and may not cause symptoms. 
• Osteomyelitis: It is a bacterial or fungal infection of the bone. It can cause localized pain, swelling, and tenderness and may present with systemic symptoms such as fever. 
• Bone Cysts: Simple or aneurysmal bone cysts can present as cystic lesions in the bone, leading to pain and swelling. They are generally benign but may require evaluation to rule out malignancy. 
• Fibrous Dysplasia: It is a bone disorder characterized by the replacement of normal bone with fibrous tissue. It may cause pain and deformity, but it is generally benign. 
• Metastatic Bone Tumors: Secondary bone tumors, resulting from metastasis of cancers from other organs, can mimic primary bone tumors. However, the clinical history and imaging characteristics can often help distinguish metastatic lesions. 
• Reactive Bone Lesions: Reactive conditions, such as benign bone lesions in response to trauma or inflammation, may cause localized pain and swelling. These are often non-neoplastic and resolve with time. 
• Synovial Sarcoma: It is a soft tissue sarcoma that may occur near joints. It can sometimes involve adjacent bone and present with symptoms similar to osteosarcoma. 
• Osteoblastoma: It is a benign bone tumor that may cause localized pain and swelling. It is important to differentiate it from osteosarcoma, which is malignant. 

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

The treatment of osteosarcoma typically involves a multimodal approach, incorporating surgery and chemotherapy. The specific treatment plan may vary based on factors such as the extent of the disease, the location of the tumor, the presence of metastases, and the patient’s overall health.  

• Biopsy and Diagnosis: Osteosarcoma is confirmed through a biopsy, which involves taking a sample of the tumor tissue for histological examination. This is a crucial step in determining the type of osteosarcoma and guiding treatment decisions. 

• Neoadjuvant Chemotherapy: Neoadjuvant chemotherapy is often administered before surgery. The goal is to shrink the tumor, control micrometastatic disease, and assess the tumor’s response to chemotherapy. Commonly used chemotherapy agents include doxorubicin, cisplatin, and high-dose methotrexate. 
• Surgery: Surgical resection of the primary tumor is a critical component of treatment. The extent of surgery depends on factors such as the size and location of the tumor. Limb-salvage surgery is preferred when possible to preserve limb function. In cases where limb salvage is not feasible, amputation may be considered. Clear surgical margins (complete removal of the tumor) are crucial for minimizing the risk of local recurrence. 
• Adjuvant Chemotherapy: Following surgery, adjuvant chemotherapy is continued to eliminate any remaining cancer cells and reduce the risk of recurrence. The duration and specific chemotherapy regimen may vary, but it typically involves a combination of drugs administered in cycles over several months. 
• Radiation Therapy: Radiation therapy may be considered in some instances, particularly for tumors that are difficult to resect completely or when the surgical margin is close or positive. It is not a routine part of treatment for all osteosarcomas but may be used in specific situations. 
• Metastatic Disease: If there is evidence of metastasis at the time of diagnosis, treatment may include more intensive chemotherapy regimens and, in some cases, surgical removal of metastatic lesions. Lung metastases, which are common in osteosarcoma, may be managed with surgery or additional chemotherapy. 

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

use-of-a-non-pharmacological-approach-for-treating-osteosarcoma

Osteosarcoma is primarily treated through a combination of surgery and chemotherapy, and non-pharmacological approaches typically play a supportive role in managing symptoms, improving overall well-being, and enhancing the patient’s quality of life.  

Surgical Interventions: 

• Limb-Sparing Techniques: Surgical procedures aim to remove the tumor while preserving limb function whenever possible. Advances in limb-sparing surgical techniques and prosthetic limb reconstruction contribute to maintaining mobility and quality of life. 

Physical Therapy: 

• Rehabilitation: Physical therapy is crucial for individuals undergoing surgery. Rehabilitation helps restore function, improve range of motion, and enhance strength. It plays a vital role in regaining mobility after limb-sparing surgeries. 

Psychosocial Support: 

• Counseling and Support Groups: A cancer diagnosis can be emotionally challenging. Psychosocial support, including counseling and participation in support groups, helps patients and their families cope with the emotional and psychological aspects of the disease and its treatment. 

Nutritional Support: 

• Nutrition Counseling: Maintaining good nutrition is essential for overall health during cancer treatment. Nutritional support, including counseling from registered dietitians, helps ensure that patients receive adequate nutrients to support healing and maintain strength. 

Pain Management: 

• Palliative Care: Non-pharmacological approaches, such as physical therapies, acupuncture, or relaxation techniques, can complement pharmacological pain management strategies to enhance pain relief and improve overall comfort. 

Assistive Devices: 

• Mobility Aids: Depending on the surgical procedure and its impact on mobility, individuals may benefit from assistive devices such as crutches, canes, or orthopedic braces to support their daily activities. 

Occupational Therapy: 

• Adaptive Equipment: Occupational therapy can assist in adapting daily activities and recommending assistive devices to improve independence and quality of life. 

Complementary and Alternative Medicine (CAM): 

• Acupuncture and Massage Therapy: Some patients find relief from symptoms such as pain and anxiety through complementary approaches like acupuncture or massage therapy. However, it’s crucial to discuss these options with the healthcare team to ensure they align with the overall treatment plan. 

Educational Support: 

• Patient Education: Providing information and resources about osteosarcoma, its treatment, and potential side effects can empower patients to participate in their care and make informed decisions actively. 

Role of chemotherapy agents in the treatment of Osteosarcoma

Chemotherapy plays a crucial role in the treatment of osteosarcoma, a type of bone cancer. Chemotherapy agents are systemic medications that circulate throughout the body, targeting and killing cancer cells.

Osteosarcoma is known for its aggressive nature and tendency to metastasize, and chemotherapy is often employed to address both the primary tumor and potential metastatic disease.  

Neoadjuvant (Preoperative) Chemotherapy: 

• Neoadjuvant chemotherapy is administered before surgery with the goal of shrinking the primary tumor. 
• By reducing the size of the tumor, neoadjuvant chemotherapy may make surgical resection more feasible and increase the likelihood of achieving negative surgical margins. 

Adjuvant (Postoperative) Chemotherapy: 

• Adjuvant chemotherapy is given after surgery to eliminate any remaining cancer cells and reduce the risk of local recurrence and metastasis. 
• The choice of chemotherapy agents and duration is determined based on the specific treatment protocol and the patient’s individual characteristics. 

Methotrexate: High-dose methotrexate is a cornerstone of osteosarcoma treatment. It interferes with the growth of cancer cells by inhibiting the synthesis of DNA and RNA. 

Doxorubicin (Adriamycin): Doxorubicin is a cytotoxic drug that works by intercalating with DNA, disrupting its structure and inhibiting DNA and RNA synthesis. 

Cisplatin: Cisplatin is a platinum-based chemotherapy agent that forms DNA adducts, leading to DNA cross-linking and inhibition of cell division. 

Ifosfamide: Ifosfamide is an alkylating agent that interferes with DNA replication and RNA transcription, leading to cell death. 

Combination Chemotherapy Regimens: 

• Osteosarcoma is often treated with a combination of chemotherapy drugs, such as the MAP regimen (Methotrexate, Adriamycin, and Cisplatin). 
• The combination approach helps target cancer cells through different mechanisms of action, reducing the risk of resistance. 

Role of bisphosphonates in the treatment of osteosarcoma

Bisphosphonates are a class of medications that have been primarily used to manage bone-related conditions, such as osteoporosis and bone metastases from certain cancers.

However, the role of bisphosphonates in the treatment of osteosarcoma, a primary bone cancer, is limited, and their use is not considered a standard part of the primary treatment strategy for this particular cancer. 

The primary treatment modalities for osteosarcoma typically include surgery and chemotherapy. Surgery aims to remove the tumor, and chemotherapy is administered to target cancer cells both locally and systemically. 

Bone Pain and Hypercalcemia: 

• Bisphosphonates may be used to manage bone pain and hypercalcemia associated with osteosarcoma. 
• These medications can help alleviate symptoms and improve the patient’s quality of life. 

Bone Metastases: 

• In rare cases where osteosarcoma has spread to other bones and caused bone metastases, bisphosphonates may be considered to address complications related to bone involvement. 
• Bisphosphonates can help reduce the risk of fractures and bone-related events in the presence of metastatic disease. 

Adjuvant Treatment: 

• Some studies have explored the use of bisphosphonates as adjuvant therapy after surgical resection of osteosarcoma to prevent bone-related complications.  

Guidelines for the Management of Osteosarcoma: A Multidisciplinary Approach Based on Tumour Grade, Location, and Metastasis

OSTEO-1 (Low-Grade Osteosarcoma, No Metastasis): 

Intramedullary and Surface: 

• Wide excision alone is recommended, with no neoadjuvant chemotherapy. 
• Adjuvant chemotherapy may be considered if postsurgical pathology demonstrates high-grade features. 

Periosteal: 

• Neoadjuvant chemotherapy is recommended, followed by a wide excision. 
• Adjuvant chemotherapy may be considered based on postsurgical pathology. 

OSTEO-2 (High-Grade Intramedullary or Surface Osteosarcoma, No Metastasis): 

• Neoadjuvant Chemotherapy: Administer neoadjuvant chemotherapy, then restage the lesion. 
• Positive Margins: Depending on how the patient responds to neoadjuvant chemotherapy, you may need to consider radiation therapy or more surgery. 
• Negative Margins: No further resection is required if there is an excellent response to neoadjuvant chemotherapy. 
• Unresectable Lesion: Continue chemotherapy and consider radiation therapy. 

OSTEO-3 (Any Grade With Metastasis at Presentation): 

• Resectable Metastases: Perform metastasectomy following OSTEO-2 guidelines. 
• Unresectable Metastases: Consider chemotherapy and radiation therapy; reassess the primary site for local control. 

OSTEO-4 (Follow-up & Surveillance): 

• Surveillance Schedule: Regular follow-up visits with varying intervals and imaging studies based on the postoperative year. 
• Relapse Detection: If relapse is detected, treatment options include chemotherapy, resection (if possible), and subsequent evaluation. 

Response to Treatment: 

Good response: Surveillance according to OSTEO-4 guidelines. 

Poor response/progression: Consider resection (if possible), clinical trial, palliative radiation, or best supportive care. 

use-of-intervention-with-a-procedure-in-treating-osteosarcoma

Surgical Intervention: 

• Limb-salvage surgery: Whenever possible, surgeons aim to remove the cancerous tissue while preserving the affected limb. This may involve the removal of the tumor along with a portion of the bone, followed by reconstruction using bone grafts or prosthetic implants. 
• Amputation: In cases where limb-salvage surgery is not feasible, amputation may be necessary to completely remove the cancerous tissue. 
• Biopsy: An interventional procedure involving the removal of a small sample of tissue for pathological examination, confirming the diagnosis of osteosarcoma. 

Chemotherapy: 

• Intravenous Chemotherapy: Interventional procedures involve the administration of chemotherapy drugs directly into the bloodstream. This can be done through a central venous catheter, which is often inserted under image guidance. 
• Intra-arterial Chemotherapy: Some studies explore the use of intra-arterial chemotherapy, where drugs are delivered directly into the arteries supplying the tumor. This method aims to maximize drug concentration in the tumor while minimizing systemic side effects. 

Radiation Therapy: 

• Interventional Radiology Procedures: In some cases, interventional radiology procedures may be used for localized delivery of radiation to the tumor site. This can include techniques like brachytherapy, where a radioactive source is placed directly within or near the tumor. 

Clinical Trials: 

• Interventional Studies: Patients with osteosarcoma may participate in clinical trials, which often involve innovative interventional approaches such as targeted therapies, immunotherapies, or novel drug delivery methods. 

use-of-phases-in-managing-osteosarcoma

Preoperative Phase: 

• Diagnosis and Staging: Accurate diagnosis and staging of osteosarcoma are crucial. This involves a combination of imaging studies (X-rays, CT scans, MRI), biopsy for histological confirmation, and possibly other tests to determine the extent of the disease. 
• Neoadjuvant Chemotherapy: Many treatment protocols start with neoadjuvant chemotherapy before surgery. The goal is to shrink the tumor, making surgical resection more feasible and potentially improving the prognosis. This phase helps assess the tumor’s response to chemotherapy, guiding further treatment decisions. 
• Preliminary Assessment for Limb-Salvage Surgery: If limb-salvage surgery is considered, preoperative planning involves assessing the feasibility of preserving the affected limb. This may include imaging studies and consultations with orthopedic surgeons and reconstructive surgeons. 

Operative Phase: 

• Surgery: The primary treatment for osteosarcoma involves surgical resection of the tumor. Depending on the extent of the disease and the response to neoadjuvant chemotherapy, surgeons may perform limb-salvage surgery or amputation. Orthopedic surgeons lead the surgical team, and reconstructive surgeons may be involved in limb-salvage procedures. 
• Biopsy Confirmation: If not done previously, a biopsy may be performed during surgery to confirm the absence of viable tumor cells after neoadjuvant chemotherapy. 

Postoperative Phase: 

• Adjuvant Chemotherapy: Following surgery, patients often undergo adjuvant chemotherapy to eliminate any remaining cancer cells and reduce the risk of recurrence. The choice of chemotherapy agents and duration is determined by the patient’s response to neoadjuvant chemotherapy and the specific treatment protocol. 
• Rehabilitation and Follow-Up: Rehabilitation is crucial for patients undergoing limb-salvage surgery to regain function and mobility. Regular follow-up appointments, imaging studies, and monitoring for potential complications or recurrence are essential during the postoperative phase. 

Long-Term Follow-Up: 

• Survivorship Care: Osteosarcoma survivors require long-term follow-up care to monitor for late effects of treatment, manage potential complications, and address psychosocial aspects of survivorship. 

Clinical Trials and Innovative Therapies: 

• Exploration of New Therapies: Participation in clinical trials may occur at various phases of osteosarcoma management, providing access to innovative treatments and contributing to advancements in cancer care. 

Medication

Future Trends

Media Gallary

References

Osteosarcoma:ncbi.nlm.nih